Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Par pharmaceutical begins shipment of generic risperdal m-tab
Par Pharmaceutical, 06/03/09

Woodcliff Lake, NJ, June 2009 Par Pharmaceutical Companies, Inc. announced that it began shipping 0.25 mg, 3 mg and 4 mg strengths of risperidone ODT to the trade. Risperidone ODT is a generic version of Janssen Pharma's Risperdal M-TAB. Annual U.S. sales of Risperdal M-TAB were approximately $89 million in 2008, according to IMS Health data. Par has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for these three strengths of the product.


Today in Marketing/Media/ROI...keeping you current

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

EMEA recommends authorization of swine flu vaccines
Pharmaceutical Technology, 10/14/09

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

See All of Marketing/Media/ROI

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address